• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » All hype, no bite

All hype, no bite

August 13, 2010 By Benjamin Smith

Seidler Bernstein logo

"Does anyone need an invitation to Google Wave?"

That was the tweet to be looking out for last year. Google Wave was yet another buzzword I had been hearing about. Like many new things, I eagerly wanted to be part of it. After all, it is my job to be in the know when it comes to the digital world.

What is (or was) Google Wave, you ask? Let me set the Wayback Machine to May 2009. That’s a long time ago when you’re talking Internet. Google announced it was working on an application that sounded like it was going to be the end of e-mail and possibly social media as we knew it.

You would be able to collaborate on projects with people online in real time, exchanging files, photos, videos, etc. It sounded very promising and would come in super-handy when working on group assignments.

It started off as invite-only and everyone in my field was looking to get access to this service and test it out. I got my invite and used it for about 30 minutes. I expected to collaborate with other people right away, but was sadly disappointed by the lack of people actually using it. Really? After all the buzz, I had been ready to delete all my e-mail and social networking accounts. Well … maybe not just yet. I suddenly realized that this service might have been greatly over-hyped.

Last week, Google announced that it would no longer be working on the Google Wave project because it "has not seen the user adoption we would have liked." No kidding. Anyone I talked to about Google Wave said the same thing: "It’s a good concept, but not enough people are on it." Google was looking for its new idea to be accepted instantly, but it forgot about one thing: The user.

As we in the medical device world know well, testing is a very important part of a launch. And in the digital world, the invite/try-us-out method works well for the beta stage (i.e., the early testing phase of a website). In the case of Google Wave, however, it never seemed clear that it was a finished product and open to the public. The tryout wore out its welcome.

And so it occurred to me that when launching a new product, not just websites, it’s important to ask yourself these questions:

  • How is this different or drastically better than anything else out there right now? What is it replacing? Is it ready?
  • Are you able to explain the purpose of your product easily?
  • Does it accomplish everything exactly the way you said it would?
  • Are people likely to tell others about your product?
  • Perhaps more important, are you making it easy for them to do that?

We live in an age when things move extremely fast and, as a result, people are attracted to momentum. So once you have the customer’s attention, you’d better make the most of it or your Wave may crash. If you want your idea to be a success in the digital age, keep in mind: The user is king. Just ask Google.

Ben SmithBenjamin Smith is the lead developer at Seidler Bernstein where he applies his considerable technology skills to a wide range of interactive projects. Ben works closely with his colleagues on the creative and account teams to bring client brand strategies to digital life. Ben keeps SBI and its clients leading-edge of technology with enthusiasm and good humor.

Filed Under: Business/Financial News, News Well Tagged With: Seidler Bernstein Inc.

In case you missed it

  • Butterfly Network asks judge to dismiss Fujifilm Sonosite IP suit
  • Stereotaxis stock down amid cloudy outlook
  • BD, Labcorp collaborate on flow cytometry-based diagnostics
  • NeuroOne submits special FDA 510(k) application for Evo sEEG electrode
  • Si-Bone grows sales 15% in Q2
  • FDA approves second IDE study for CereVasc eShunt
  • Nuwellis posts Q2 sales beat
  • Avanos Medical updates full-year revenue guidance on mixed-bag Q2 results
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • Conformis rises on in-line Q2 results
  • ICU Medical stock sinks on Q2 misses, slashed 2022 guidance
  • Vicarious Surgical completes Beta 2 system design
  • Asensus Surgical says procedures up by more than a third in Q2
  • MRI pioneer Dr. Raymond Damadian dies at 86
  • BD makes tender offers for up to $500M of its debt
  • ViewRay moves HQ to Denver
  • Abbott is looking to address biases for cardiovascular patients

RSS From Medical Design & Outsourcing

  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]
  • New method of cardiac ablation used in first in-human trial for ventricular tachycardia
    A new cardiac ablation technique for patients with ventricular tachycardia (VT) has been used in its first in-human multicenter trial involving Mayo Clinic. The new process — needle ablation using in-catheter, heated, saline-enhanced, radio frequency (SERF) energy — creates lesion scars inside the heart muscle where life-threatening arrhythmias cause VT, Mayo Clinic said. Injecting heated saline… […]
  • AdvaMed pushes CMS for proposed TCET pathway rule this year
    The Advanced Medical Technology Association (AdvaMed) is asking the Centers for Medicare & Medicaid Services (CMS) to move fast on a new way to guarantee reimbursement for new medtech innovations. CMS repealed the Medicare Coverage of Innovative Technology (MCIT) program last year but promised to explore other options to improve the coverage process for access… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy